#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Protein N-glycosylation is a critical post-translational modification , in which an oligosaccharide moiety is transferred from the glycosyl carrier dolichol-phosphate ( Dol-P ) and covalently attaches to a polypeptide chain via an asparagine residue .
2-1	16-23	Protein	substance|event[3]	new|new[3]	coref|coref	2-4[4_3]|3-2
2-2	24-39	N-glycosylation	event[3]	new[3]	_	_
2-3	40-42	is	_	_	_	_
2-4	43-44	a	event[4]	giv[4]	coref	4-3[20_4]
2-5	45-53	critical	event[4]	giv[4]	_	_
2-6	54-72	post-translational	event[4]	giv[4]	_	_
2-7	73-85	modification	event[4]	giv[4]	_	_
2-8	86-87	,	event[4]	giv[4]	_	_
2-9	88-90	in	event[4]	giv[4]	_	_
2-10	91-96	which	event[4]	giv[4]	_	_
2-11	97-99	an	event[4]|object[6]	giv[4]|new[6]	_	_
2-12	100-115	oligosaccharide	event[4]|abstract|object[6]	giv[4]|new|new[6]	coref	3-5[17_0]
2-13	116-122	moiety	event[4]|object[6]	giv[4]|new[6]	_	_
2-14	123-125	is	event[4]	giv[4]	_	_
2-15	126-137	transferred	event[4]	giv[4]	_	_
2-16	138-142	from	event[4]	giv[4]	_	_
2-17	143-146	the	event[4]|substance[9]	giv[4]|new[9]	appos	2-22[0_9]
2-18	147-155	glycosyl	event[4]|abstract|organization[8]|substance[9]	giv[4]|new|new[8]|new[9]	_	_
2-19	156-163	carrier	event[4]|organization[8]|substance[9]	giv[4]|new[8]|new[9]	_	_
2-20	164-182	dolichol-phosphate	event[4]|substance[9]	giv[4]|new[9]	_	_
2-21	183-184	(	event[4]	giv[4]	_	_
2-22	185-190	Dol-P	event[4]|substance	giv[4]|giv	coref	7-21
2-23	191-192	)	event[4]	giv[4]	_	_
2-24	193-196	and	event[4]	giv[4]	_	_
2-25	197-207	covalently	event[4]	giv[4]	_	_
2-26	208-216	attaches	event[4]	giv[4]	_	_
2-27	217-219	to	_	_	_	_
2-28	220-221	a	object[12]	new[12]	_	_
2-29	222-233	polypeptide	place|object[12]	new|new[12]	_	_
2-30	234-239	chain	object[12]	new[12]	_	_
2-31	240-243	via	_	_	_	_
2-32	244-246	an	object[14]	new[14]	_	_
2-33	247-257	asparagine	substance|object[14]	new|new[14]	_	_
2-34	258-265	residue	object[14]	new[14]	_	_
2-35	266-267	.	_	_	_	_

#Text=Following protein conjugation , the oligosaccharide is further modified , increasing the functional and structural diversity of the proteome .
3-1	268-277	Following	_	_	_	_
3-2	278-285	protein	substance|abstract[16]	giv|new[16]	coref	4-9
3-3	286-297	conjugation	abstract[16]	new[16]	_	_
3-4	298-299	,	_	_	_	_
3-5	300-303	the	abstract[17]	giv[17]	_	_
3-6	304-319	oligosaccharide	abstract[17]	giv[17]	_	_
3-7	320-322	is	_	_	_	_
3-8	323-330	further	_	_	_	_
3-9	331-339	modified	_	_	_	_
3-10	340-341	,	_	_	_	_
3-11	342-352	increasing	_	_	_	_
3-12	353-356	the	abstract[18]	new[18]	_	_
3-13	357-367	functional	abstract[18]	new[18]	_	_
3-14	368-371	and	abstract[18]	new[18]	_	_
3-15	372-382	structural	abstract[18]	new[18]	_	_
3-16	383-392	diversity	abstract[18]	new[18]	_	_
3-17	393-395	of	abstract[18]	new[18]	_	_
3-18	396-399	the	abstract[18]|animal[19]	new[18]|new[19]	_	_
3-19	400-408	proteome	abstract[18]|animal[19]	new[18]|new[19]	_	_
3-20	409-410	.	_	_	_	_

#Text=Indeed , this modification is crucial for proper protein folding , oligomerization , quality control , sorting , and transport .
4-1	411-417	Indeed	_	_	_	_
4-2	418-419	,	_	_	_	_
4-3	420-424	this	event[20]	giv[20]	_	_
4-4	425-437	modification	event[20]	giv[20]	_	_
4-5	438-440	is	_	_	_	_
4-6	441-448	crucial	_	_	_	_
4-7	449-452	for	_	_	_	_
4-8	453-459	proper	event[22]	new[22]	_	_
4-9	460-467	protein	substance|event[22]	giv|new[22]	coref	5-7
4-10	468-475	folding	event[22]	new[22]	_	_
4-11	476-477	,	_	_	_	_
4-12	478-493	oligomerization	place	new	_	_
4-13	494-495	,	_	_	_	_
4-14	496-503	quality	abstract[24]	new[24]	_	_
4-15	504-511	control	abstract[24]	new[24]	_	_
4-16	512-513	,	_	_	_	_
4-17	514-521	sorting	abstract	new	_	_
4-18	522-523	,	_	_	_	_
4-19	524-527	and	_	_	_	_
4-20	528-537	transport	event	new	_	_
4-21	538-539	.	_	_	_	_

#Text=Accordingly , even slight variations in protein glycosylation can markedly affect proteins structure and function and , thus , glycosylation disorders result in a wide range of clinical syndromes affecting practically every organ system .
5-1	540-551	Accordingly	_	_	_	_
5-2	552-553	,	_	_	_	_
5-3	554-558	even	abstract[27]	new[27]	_	_
5-4	559-565	slight	abstract[27]	new[27]	_	_
5-5	566-576	variations	abstract[27]	new[27]	_	_
5-6	577-579	in	abstract[27]	new[27]	_	_
5-7	580-587	protein	abstract[27]|substance|abstract[29]	new[27]|giv|new[29]	coref|coref	5-20[0_29]|12-10
5-8	588-601	glycosylation	abstract[27]|abstract[29]	new[27]|new[29]	_	_
5-9	602-605	can	_	_	_	_
5-10	606-614	markedly	_	_	_	_
5-11	615-621	affect	_	_	_	_
5-12	622-630	proteins	substance|abstract[31]|abstract[32]	new|new[31]|new[32]	coref|coref	20-3[123_31]|20-3[124_32]
5-13	631-640	structure	abstract[31]|abstract[32]	new[31]|new[32]	_	_
5-14	641-644	and	abstract[32]	new[32]	_	_
5-15	645-653	function	abstract[32]|abstract	new[32]|new	_	_
5-16	654-657	and	_	_	_	_
5-17	658-659	,	_	_	_	_
5-18	660-664	thus	_	_	_	_
5-19	665-666	,	_	_	_	_
5-20	667-680	glycosylation	abstract|abstract[35]	giv|new[35]	coref	12-10[79_0]
5-21	681-690	disorders	abstract[35]	new[35]	_	_
5-22	691-697	result	_	_	_	_
5-23	698-700	in	_	_	_	_
5-24	701-702	a	abstract[36]	new[36]	_	_
5-25	703-707	wide	abstract[36]	new[36]	_	_
5-26	708-713	range	abstract[36]	new[36]	_	_
5-27	714-716	of	abstract[36]	new[36]	_	_
5-28	717-725	clinical	abstract[36]|abstract[37]	new[36]|new[37]	_	_
5-29	726-735	syndromes	abstract[36]|abstract[37]	new[36]|new[37]	_	_
5-30	736-745	affecting	abstract[36]|abstract[37]	new[36]|new[37]	_	_
5-31	746-757	practically	abstract[36]|abstract[37]|abstract[39]	new[36]|new[37]|new[39]	_	_
5-32	758-763	every	abstract[36]|abstract[37]|abstract[39]	new[36]|new[37]|new[39]	_	_
5-33	764-769	organ	abstract[36]|abstract[37]|object|abstract[39]	new[36]|new[37]|new|new[39]	_	_
5-34	770-776	system	abstract[36]|abstract[37]|abstract[39]	new[36]|new[37]|new[39]	_	_
5-35	777-778	.	_	_	_	_

#Text=Dehydrodolichyl diphosphate synthase ( DHDDS ) together with Nogo-B receptor ( NgBR ) form the human cis -prenyltransferase complex .
6-1	779-794	Dehydrodolichyl	abstract|abstract[41]|abstract[42]	new|new[41]|new[42]	appos|coref|coref	6-5[0_42]|7-7|7-7[52_41]
6-2	795-806	diphosphate	abstract[41]|abstract[42]	new[41]|new[42]	_	_
6-3	807-815	synthase	abstract[42]	new[42]	_	_
6-4	816-817	(	_	_	_	_
6-5	818-823	DHDDS	abstract	giv	coref	11-8
6-6	824-825	)	_	_	_	_
6-7	826-834	together	substance[45]	new[45]	_	_
6-8	835-839	with	substance[45]	new[45]	_	_
6-9	840-846	Nogo-B	animal|substance[45]	new|new[45]	_	_
6-10	847-855	receptor	substance[45]	new[45]	_	_
6-11	856-857	(	_	_	_	_
6-12	858-862	NgBR	abstract	new	coref	11-18
6-13	863-864	)	_	_	_	_
6-14	865-869	form	event	new	coref|none	7-4[50_0]|6-14[0_50]
6-15	870-873	the	abstract[48]	new[48]	coref	7-1[49_48]
6-16	874-879	human	abstract[48]	new[48]	_	_
6-17	880-883	cis	abstract|abstract[48]	new|new[48]	coref	14-34
6-18	884-902	-prenyltransferase	abstract[48]	new[48]	_	_
6-19	903-910	complex	abstract[48]	new[48]	_	_
6-20	911-912	.	_	_	_	_

#Text=This complex catalyzes the formation of dehydrodolichyl diphosphate ( DHDD ) , a long-chain polyprenyl serving as a precursor for Dol-P .
7-1	913-917	This	abstract[49]	giv[49]	coref	11-28[74_49]
7-2	918-925	complex	abstract[49]	giv[49]	_	_
7-3	926-935	catalyzes	_	_	_	_
7-4	936-939	the	event[50]	new[50]	_	_
7-5	940-949	formation	event[50]	new[50]	_	_
7-6	950-952	of	event[50]	new[50]	_	_
7-7	953-968	dehydrodolichyl	event[50]|abstract|abstract[52]	new[50]|giv|giv[52]	appos	7-10[0_52]
7-8	969-980	diphosphate	event[50]|abstract[52]	new[50]|giv[52]	_	_
7-9	981-982	(	_	_	_	_
7-10	983-987	DHDD	abstract	giv	appos	7-13[54_0]
7-11	988-989	)	_	_	_	_
7-12	990-991	,	_	_	_	_
7-13	992-993	a	abstract[54]	giv[54]	coref	8-1[0_54]
7-14	994-1004	long-chain	abstract[54]	giv[54]	_	_
7-15	1005-1015	polyprenyl	abstract[54]	giv[54]	_	_
7-16	1016-1023	serving	abstract[54]	giv[54]	_	_
7-17	1024-1026	as	abstract[54]	giv[54]	_	_
7-18	1027-1028	a	abstract[54]|substance[55]	giv[54]|new[55]	_	_
7-19	1029-1038	precursor	abstract[54]|substance[55]	giv[54]|new[55]	_	_
7-20	1039-1042	for	abstract[54]|substance[55]	giv[54]|new[55]	_	_
7-21	1043-1048	Dol-P	abstract[54]|substance[55]|substance	giv[54]|new[55]|giv	_	_
7-22	1049-1050	.	_	_	_	_

#Text=DHDD is synthesized by chain elongation of farnesyl diphosphate ( FPP ) via multiple condensations with isopentenyl diphosphate ( IPP ) (
8-1	1051-1055	DHDD	abstract	giv	coref	8-8[60_0]
8-2	1056-1058	is	_	_	_	_
8-3	1059-1070	synthesized	_	_	_	_
8-4	1071-1073	by	_	_	_	_
8-5	1074-1079	chain	event[58]	new[58]	_	_
8-6	1080-1090	elongation	event[58]	new[58]	_	_
8-7	1091-1093	of	event[58]	new[58]	_	_
8-8	1094-1102	farnesyl	event[58]|abstract|abstract[60]	new[58]|new|giv[60]	coref	8-17[64_60]
8-9	1103-1114	diphosphate	event[58]|abstract[60]	new[58]|giv[60]	_	_
8-10	1115-1116	(	_	_	_	_
8-11	1117-1120	FPP	abstract	new	_	_
8-12	1121-1122	)	_	_	_	_
8-13	1123-1126	via	_	_	_	_
8-14	1127-1135	multiple	abstract[62]	new[62]	_	_
8-15	1136-1149	condensations	abstract[62]	new[62]	_	_
8-16	1150-1154	with	abstract[62]	new[62]	_	_
8-17	1155-1166	isopentenyl	abstract[62]|abstract|abstract[64]	new[62]|new|giv[64]	_	_
8-18	1167-1178	diphosphate	abstract[62]|abstract[64]	new[62]|giv[64]	_	_
8-19	1179-1180	(	_	_	_	_
8-20	1181-1184	IPP	abstract	new	_	_
8-21	1185-1186	)	_	_	_	_
8-22	1187-1188	(	_	_	_	_

#Text=Figure 1
9-1	1189-1195	Figure	abstract[66]	new[66]	coref	18-1[120_66]
9-2	1196-1197	1	abstract[66]	new[66]	_	_

#Text=A ) .
10-1	1198-1199	A	_	_	_	_
10-2	1200-1201	)	_	_	_	_
10-3	1202-1203	.	_	_	_	_

#Text=Importantly , while previous studies revealed that DHDDS is required and sufficient for this catalytic activity , NgBR induces an increase in the expression and activity of the complex but exhibits no catalytic activity .
11-1	1204-1215	Importantly	_	_	_	_
11-2	1216-1217	,	_	_	_	_
11-3	1218-1223	while	_	_	_	_
11-4	1224-1232	previous	abstract[67]	new[67]	_	_
11-5	1233-1240	studies	abstract[67]	new[67]	_	_
11-6	1241-1249	revealed	_	_	_	_
11-7	1250-1254	that	_	_	_	_
11-8	1255-1260	DHDDS	abstract	giv	coref	12-8
11-9	1261-1263	is	_	_	_	_
11-10	1264-1272	required	_	_	_	_
11-11	1273-1276	and	_	_	_	_
11-12	1277-1287	sufficient	_	_	_	_
11-13	1288-1291	for	_	_	_	_
11-14	1292-1296	this	abstract[69]	new[69]	coref	11-26[73_69]
11-15	1297-1306	catalytic	abstract[69]	new[69]	_	_
11-16	1307-1315	activity	abstract[69]	new[69]	_	_
11-17	1316-1317	,	_	_	_	_
11-18	1318-1322	NgBR	abstract	giv	_	_
11-19	1323-1330	induces	_	_	_	_
11-20	1331-1333	an	event[71]	new[71]	_	_
11-21	1334-1342	increase	event[71]	new[71]	_	_
11-22	1343-1345	in	event[71]	new[71]	_	_
11-23	1346-1349	the	event[71]|abstract[72]	new[71]|new[72]	_	_
11-24	1350-1360	expression	event[71]|abstract[72]	new[71]|new[72]	_	_
11-25	1361-1364	and	event[71]	new[71]	_	_
11-26	1365-1373	activity	event[71]|abstract[73]	new[71]|giv[73]	coref	11-32[75_73]
11-27	1374-1376	of	event[71]|abstract[73]	new[71]|giv[73]	_	_
11-28	1377-1380	the	event[71]|abstract[73]|abstract[74]	new[71]|giv[73]|giv[74]	_	_
11-29	1381-1388	complex	event[71]|abstract[73]|abstract[74]	new[71]|giv[73]|giv[74]	_	_
11-30	1389-1392	but	_	_	_	_
11-31	1393-1401	exhibits	_	_	_	_
11-32	1402-1404	no	abstract[75]	giv[75]	_	_
11-33	1405-1414	catalytic	abstract[75]	giv[75]	_	_
11-34	1415-1423	activity	abstract[75]	giv[75]	_	_
11-35	1424-1425	.	_	_	_	_

#Text=In line with the important role of DHDDS in protein glycosylation , mutations in DHDDS were recently shown to cause autosomal recessive retinitis pigmentosa , a fatal glycosylation disorder , and developmental epileptic encephalopathies .
12-1	1426-1428	In	_	_	_	_
12-2	1429-1433	line	_	_	_	_
12-3	1434-1438	with	_	_	_	_
12-4	1439-1442	the	abstract[76]	new[76]	coref	20-6[125_76]
12-5	1443-1452	important	abstract[76]	new[76]	_	_
12-6	1453-1457	role	abstract[76]	new[76]	_	_
12-7	1458-1460	of	abstract[76]	new[76]	_	_
12-8	1461-1466	DHDDS	abstract[76]|abstract	new[76]|giv	coref	12-15
12-9	1467-1469	in	abstract[76]	new[76]	_	_
12-10	1470-1477	protein	abstract[76]|substance|abstract[79]	new[76]|giv|giv[79]	coref	12-28[0_79]
12-11	1478-1491	glycosylation	abstract[76]|abstract[79]	new[76]|giv[79]	_	_
12-12	1492-1493	,	_	_	_	_
12-13	1494-1503	mutations	abstract[80]	new[80]	_	_
12-14	1504-1506	in	abstract[80]	new[80]	_	_
12-15	1507-1512	DHDDS	abstract[80]|abstract	new[80]|giv	coref	13-6
12-16	1513-1517	were	_	_	_	_
12-17	1518-1526	recently	_	_	_	_
12-18	1527-1532	shown	_	_	_	_
12-19	1533-1535	to	_	_	_	_
12-20	1536-1541	cause	_	_	_	_
12-21	1542-1551	autosomal	animal[83]	new[83]	_	_
12-22	1552-1561	recessive	animal[83]	new[83]	_	_
12-23	1562-1571	retinitis	event|animal[83]	new|new[83]	_	_
12-24	1572-1582	pigmentosa	animal[83]	new[83]	_	_
12-25	1583-1584	,	_	_	_	_
12-26	1585-1586	a	abstract[85]	new[85]	_	_
12-27	1587-1592	fatal	abstract[85]	new[85]	_	_
12-28	1593-1606	glycosylation	abstract|abstract[85]	giv|new[85]	_	_
12-29	1607-1615	disorder	abstract[85]	new[85]	_	_
12-30	1616-1617	,	_	_	_	_
12-31	1618-1621	and	_	_	_	_
12-32	1622-1635	developmental	abstract[86]	new[86]	_	_
12-33	1636-1645	epileptic	abstract[86]	new[86]	_	_
12-34	1646-1662	encephalopathies	abstract[86]	new[86]	_	_
12-35	1663-1664	.	_	_	_	_

#Text=Despite the clinical importance of DHDDS , it was not structurally and functionally characterized to date .
13-1	1665-1672	Despite	_	_	_	_
13-2	1673-1676	the	abstract[87]	new[87]	_	_
13-3	1677-1685	clinical	abstract[87]	new[87]	_	_
13-4	1686-1696	importance	abstract[87]	new[87]	_	_
13-5	1697-1699	of	abstract[87]	new[87]	_	_
13-6	1700-1705	DHDDS	abstract[87]|abstract	new[87]|giv	ana	13-8
13-7	1706-1707	,	_	_	_	_
13-8	1708-1710	it	abstract	giv	coref	14-13
13-9	1711-1714	was	_	_	_	_
13-10	1715-1718	not	_	_	_	_
13-11	1719-1731	structurally	_	_	_	_
13-12	1732-1735	and	_	_	_	_
13-13	1736-1748	functionally	_	_	_	_
13-14	1749-1762	characterized	_	_	_	_
13-15	1763-1765	to	_	_	_	_
13-16	1766-1770	date	time	new	_	_
13-17	1771-1772	.	_	_	_	_

#Text=Conserved domains search analysis reveals that the cis -prenyltransferase catalytic domain of DHDDS ( residues 24 – 248 ) is homologous to undecaprenyl pyrophosphate synthase ( UPPS ) , a well characterized bacterial cis -prenyltransferase .
14-1	1773-1782	Conserved	abstract[91]|abstract[93]	new[91]|new[93]	coref	16-20[116_91]
14-2	1783-1790	domains	abstract[91]|abstract[93]	new[91]|new[93]	_	_
14-3	1791-1797	search	event|abstract[93]	new|new[93]	_	_
14-4	1798-1806	analysis	abstract[93]	new[93]	_	_
14-5	1807-1814	reveals	_	_	_	_
14-6	1815-1819	that	_	_	_	_
14-7	1820-1823	the	abstract[94]	new[94]	coref	15-9[104_94]
14-8	1824-1827	cis	abstract[94]	new[94]	_	_
14-9	1828-1846	-prenyltransferase	abstract[94]	new[94]	_	_
14-10	1847-1856	catalytic	abstract[94]	new[94]	_	_
14-11	1857-1863	domain	abstract[94]	new[94]	_	_
14-12	1864-1866	of	abstract[94]	new[94]	_	_
14-13	1867-1872	DHDDS	abstract[94]|abstract	new[94]|giv	appos	14-15[96_0]
14-14	1873-1874	(	_	_	_	_
14-15	1875-1883	residues	abstract[96]	giv[96]	coref	14-23[99_96]
14-16	1884-1886	24	abstract[96]	giv[96]	_	_
14-17	1887-1888	–	abstract[96]	giv[96]	_	_
14-18	1889-1892	248	abstract[96]|abstract	giv[96]|new	_	_
14-19	1893-1894	)	_	_	_	_
14-20	1895-1897	is	_	_	_	_
14-21	1898-1908	homologous	_	_	_	_
14-22	1909-1911	to	_	_	_	_
14-23	1912-1924	undecaprenyl	abstract[99]	giv[99]	appos	14-27[0_99]
14-24	1925-1938	pyrophosphate	abstract|abstract[99]	new|giv[99]	_	_
14-25	1939-1947	synthase	abstract[99]	giv[99]	_	_
14-26	1948-1949	(	_	_	_	_
14-27	1950-1954	UPPS	abstract	giv	coref	16-14[115_0]
14-28	1955-1956	)	_	_	_	_
14-29	1957-1958	,	_	_	_	_
14-30	1959-1960	a	_	_	_	_
14-31	1961-1965	well	_	_	_	_
14-32	1966-1979	characterized	_	_	_	_
14-33	1980-1989	bacterial	_	_	_	_
14-34	1990-1993	cis	abstract	giv	coref	16-6
14-35	1994-2012	-prenyltransferase	_	_	_	_
14-36	2013-2014	.	_	_	_	_

#Text=Consisting of seven α-helices and six β-strands , this domain forms dimers , with a hydrophobic catalytic tunnel surrounded by two α-helices and four β−strands within each monomer .
15-1	2015-2025	Consisting	_	_	_	_
15-2	2026-2028	of	_	_	_	_
15-3	2029-2034	seven	organization[102]	new[102]	_	_
15-4	2035-2044	α-helices	organization[102]	new[102]	_	_
15-5	2045-2048	and	_	_	_	_
15-6	2049-2052	six	place[103]	new[103]	_	_
15-7	2053-2062	β-strands	place[103]	new[103]	_	_
15-8	2063-2064	,	_	_	_	_
15-9	2065-2069	this	abstract[104]	giv[104]	coref	16-4[113_104]
15-10	2070-2076	domain	abstract[104]	giv[104]	_	_
15-11	2077-2082	forms	_	_	_	_
15-12	2083-2089	dimers	abstract	new	_	_
15-13	2090-2091	,	_	_	_	_
15-14	2092-2096	with	_	_	_	_
15-15	2097-2098	a	object[106]	new[106]	_	_
15-16	2099-2110	hydrophobic	object[106]	new[106]	_	_
15-17	2111-2120	catalytic	object[106]	new[106]	_	_
15-18	2121-2127	tunnel	object[106]	new[106]	_	_
15-19	2128-2138	surrounded	object[106]	new[106]	_	_
15-20	2139-2141	by	object[106]	new[106]	_	_
15-21	2142-2145	two	object[106]|organization[107]	new[106]|new[107]	_	_
15-22	2146-2155	α-helices	object[106]|organization[107]	new[106]|new[107]	_	_
15-23	2156-2159	and	object[106]	new[106]	_	_
15-24	2160-2164	four	object[106]|place[108]	new[106]|new[108]	_	_
15-25	2165-2174	β−strands	object[106]|place[108]	new[106]|new[108]	_	_
15-26	2175-2181	within	object[106]	new[106]	_	_
15-27	2182-2186	each	object[106]|object[109]	new[106]|new[109]	_	_
15-28	2187-2194	monomer	object[106]|object[109]	new[106]|new[109]	_	_
15-29	2195-2196	.	_	_	_	_

#Text=In contrast with the N-terminal cis -prenyltransferase homology domain , the C-terminus of human DHDDS does not converge with any known conserved domains .
16-1	2197-2199	In	_	_	_	_
16-2	2200-2208	contrast	_	_	_	_
16-3	2209-2213	with	_	_	_	_
16-4	2214-2217	the	abstract[113]	giv[113]	coref	17-10[119_113]
16-5	2218-2228	N-terminal	place|abstract[113]	new|giv[113]	_	_
16-6	2229-2232	cis	abstract|abstract[113]	giv|giv[113]	_	_
16-7	2233-2251	-prenyltransferase	abstract[113]	giv[113]	_	_
16-8	2252-2260	homology	abstract|abstract[113]	new|giv[113]	_	_
16-9	2261-2267	domain	abstract[113]	giv[113]	_	_
16-10	2268-2269	,	_	_	_	_
16-11	2270-2273	the	abstract[114]	new[114]	_	_
16-12	2274-2284	C-terminus	abstract[114]	new[114]	_	_
16-13	2285-2287	of	abstract[114]	new[114]	_	_
16-14	2288-2293	human	abstract[114]|abstract[115]	new[114]|giv[115]	coref	21-14[130_115]
16-15	2294-2299	DHDDS	abstract[114]|abstract[115]	new[114]|giv[115]	_	_
16-16	2300-2304	does	_	_	_	_
16-17	2305-2308	not	_	_	_	_
16-18	2309-2317	converge	_	_	_	_
16-19	2318-2322	with	_	_	_	_
16-20	2323-2326	any	abstract[116]	giv[116]	_	_
16-21	2327-2332	known	abstract[116]	giv[116]	_	_
16-22	2333-2342	conserved	abstract[116]	giv[116]	_	_
16-23	2343-2350	domains	abstract[116]	giv[116]	_	_
16-24	2351-2352	.	_	_	_	_

#Text=Intriguingly , despite the low level of conservation , a C-terminal domain is common to long-chain cis -prenyltransferases and is absent in short- and medium-chain cis -prenyltransferases (
17-1	2353-2365	Intriguingly	_	_	_	_
17-2	2366-2367	,	_	_	_	_
17-3	2368-2375	despite	_	_	_	_
17-4	2376-2379	the	abstract[117]	new[117]	_	_
17-5	2380-2383	low	abstract[117]	new[117]	_	_
17-6	2384-2389	level	abstract[117]	new[117]	_	_
17-7	2390-2392	of	abstract[117]	new[117]	_	_
17-8	2393-2405	conservation	abstract[117]|abstract	new[117]|new	_	_
17-9	2406-2407	,	_	_	_	_
17-10	2408-2409	a	abstract[119]	giv[119]	_	_
17-11	2410-2420	C-terminal	abstract[119]	giv[119]	_	_
17-12	2421-2427	domain	abstract[119]	giv[119]	_	_
17-13	2428-2430	is	_	_	_	_
17-14	2431-2437	common	_	_	_	_
17-15	2438-2440	to	_	_	_	_
17-16	2441-2451	long-chain	_	_	_	_
17-17	2452-2455	cis	_	_	_	_
17-18	2456-2475	-prenyltransferases	_	_	_	_
17-19	2476-2479	and	_	_	_	_
17-20	2480-2482	is	_	_	_	_
17-21	2483-2489	absent	_	_	_	_
17-22	2490-2492	in	_	_	_	_
17-23	2493-2499	short-	_	_	_	_
17-24	2500-2503	and	_	_	_	_
17-25	2504-2516	medium-chain	_	_	_	_
17-26	2517-2520	cis	_	_	_	_
17-27	2521-2540	-prenyltransferases	_	_	_	_
17-28	2541-2542	(	_	_	_	_

#Text=Figure 1
18-1	2543-2549	Figure	abstract[120]	giv[120]	ana	6-14[0_120]
18-2	2550-2551	1	abstract[120]	giv[120]	_	_

#Text=B ) .
19-1	2552-2553	B	person	new	_	_
19-2	2554-2555	)	_	_	_	_
19-3	2556-2557	.	_	_	_	_

#Text=Nevertheless , its structure and functional role remains elusive .
20-1	2558-2570	Nevertheless	_	_	_	_
20-2	2571-2572	,	_	_	_	_
20-3	2573-2576	its	abstract|abstract[123]|abstract[124]	giv|giv[123]|giv[124]	_	_
20-4	2577-2586	structure	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
20-5	2587-2590	and	abstract[124]	giv[124]	_	_
20-6	2591-2601	functional	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
20-7	2602-2606	role	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
20-8	2607-2614	remains	_	_	_	_
20-9	2615-2622	elusive	_	_	_	_
20-10	2623-2624	.	_	_	_	_

#Text=Recently , we have devised an efficient procedure for overexpression and purification of human DHDDS in Escherichia coli .
21-1	2625-2633	Recently	_	_	_	_
21-2	2634-2635	,	_	_	_	_
21-3	2636-2638	we	person	acc	ana	22-8
21-4	2639-2643	have	_	_	_	_
21-5	2644-2651	devised	_	_	_	_
21-6	2652-2654	an	abstract[127]	new[127]	_	_
21-7	2655-2664	efficient	abstract[127]	new[127]	_	_
21-8	2665-2674	procedure	abstract[127]	new[127]	_	_
21-9	2675-2678	for	abstract[127]	new[127]	_	_
21-10	2679-2693	overexpression	abstract[127]|event	new[127]|new	_	_
21-11	2694-2697	and	abstract[127]	new[127]	_	_
21-12	2698-2710	purification	abstract[127]|abstract[129]	new[127]|new[129]	_	_
21-13	2711-2713	of	abstract[127]|abstract[129]	new[127]|new[129]	_	_
21-14	2714-2719	human	abstract[127]|abstract[129]|abstract[130]	new[127]|new[129]|giv[130]	coref	22-11[136_130]
21-15	2720-2725	DHDDS	abstract[127]|abstract[129]|abstract[130]	new[127]|new[129]|giv[130]	_	_
21-16	2726-2728	in	abstract[127]|abstract[129]|abstract[130]	new[127]|new[129]|giv[130]	_	_
21-17	2729-2740	Escherichia	abstract[127]|abstract[129]|abstract[130]|person|substance[132]	new[127]|new[129]|giv[130]|new|new[132]	_	_
21-18	2741-2745	coli	abstract[127]|abstract[129]|abstract[130]|substance[132]	new[127]|new[129]|giv[130]|new[132]	_	_
21-19	2746-2747	.	_	_	_	_

#Text=Similar to the bacterial homolog UPPS , we showed that human DHDDS forms active homodimers .
22-1	2748-2755	Similar	_	_	_	_
22-2	2756-2758	to	_	_	_	_
22-3	2759-2762	the	abstract[134]	new[134]	_	_
22-4	2763-2772	bacterial	abstract[134]	new[134]	_	_
22-5	2773-2780	homolog	abstract|abstract[134]	new|new[134]	_	_
22-6	2781-2785	UPPS	abstract[134]	new[134]	_	_
22-7	2786-2787	,	_	_	_	_
22-8	2788-2790	we	person	giv	ana	24-3
22-9	2791-2797	showed	_	_	_	_
22-10	2798-2802	that	_	_	_	_
22-11	2803-2808	human	abstract[136]	giv[136]	coref	24-12[0_136]
22-12	2809-2814	DHDDS	abstract[136]	giv[136]	_	_
22-13	2815-2820	forms	_	_	_	_
22-14	2821-2827	active	abstract[137]	new[137]	_	_
22-15	2828-2838	homodimers	abstract[137]	new[137]	_	_
22-16	2839-2840	.	_	_	_	_

#Text=However , the molecular details of the interaction interface and the overall architecture of the enzyme remained obscure .
23-1	2841-2848	However	_	_	_	_
23-2	2849-2850	,	_	_	_	_
23-3	2851-2854	the	abstract[138]	new[138]	_	_
23-4	2855-2864	molecular	abstract[138]	new[138]	_	_
23-5	2865-2872	details	abstract[138]	new[138]	_	_
23-6	2873-2875	of	abstract[138]	new[138]	_	_
23-7	2876-2879	the	abstract[138]|abstract[140]	new[138]|new[140]	_	_
23-8	2880-2891	interaction	abstract[138]|abstract|abstract[140]	new[138]|new|new[140]	_	_
23-9	2892-2901	interface	abstract[138]|abstract[140]	new[138]|new[140]	_	_
23-10	2902-2905	and	_	_	_	_
23-11	2906-2909	the	abstract[141]	new[141]	_	_
23-12	2910-2917	overall	abstract[141]	new[141]	_	_
23-13	2918-2930	architecture	abstract[141]	new[141]	_	_
23-14	2931-2933	of	abstract[141]	new[141]	_	_
23-15	2934-2937	the	abstract[141]|substance[142]	new[141]|new[142]	coref	24-28[0_142]
23-16	2938-2944	enzyme	abstract[141]|substance[142]	new[141]|new[142]	_	_
23-17	2945-2953	remained	_	_	_	_
23-18	2954-2961	obscure	_	_	_	_
23-19	2962-2963	.	_	_	_	_

#Text=Here , we determine a structural model for the full-length human DHDDS homodimer using an integrative approach that combines multiple sources of information , including a radioligand-based enzyme kinetics assay , size-exclusion chromatography multi-angle light scattering ( SEC-MALS ) , small-angle X-ray scattering ( SAXS ) , and hydrogen – deuterium exchange mass-spectrometry ( HDX-MS ) .
24-1	2964-2968	Here	_	_	_	_
24-2	2969-2970	,	_	_	_	_
24-3	2971-2973	we	person	giv	_	_
24-4	2974-2983	determine	_	_	_	_
24-5	2984-2985	a	abstract[144]	new[144]	_	_
24-6	2986-2996	structural	abstract[144]	new[144]	_	_
24-7	2997-3002	model	abstract[144]	new[144]	_	_
24-8	3003-3006	for	abstract[144]	new[144]	_	_
24-9	3007-3010	the	abstract[144]|abstract[146]	new[144]|new[146]	_	_
24-10	3011-3022	full-length	abstract[144]|abstract[146]	new[144]|new[146]	_	_
24-11	3023-3028	human	abstract[144]|abstract[146]	new[144]|new[146]	_	_
24-12	3029-3034	DHDDS	abstract[144]|abstract|abstract[146]	new[144]|giv|new[146]	_	_
24-13	3035-3044	homodimer	abstract[144]|abstract[146]	new[144]|new[146]	_	_
24-14	3045-3050	using	_	_	_	_
24-15	3051-3053	an	abstract[147]	new[147]	_	_
24-16	3054-3065	integrative	abstract[147]	new[147]	_	_
24-17	3066-3074	approach	abstract[147]	new[147]	_	_
24-18	3075-3079	that	abstract[147]	new[147]	_	_
24-19	3080-3088	combines	abstract[147]	new[147]	_	_
24-20	3089-3097	multiple	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-21	3098-3105	sources	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-22	3106-3108	of	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-23	3109-3120	information	abstract[147]|abstract[148]|abstract	new[147]|new[148]|new	_	_
24-24	3121-3122	,	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-25	3123-3132	including	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-26	3133-3134	a	abstract[147]|abstract[148]|abstract[152]	new[147]|new[148]|new[152]	_	_
24-27	3135-3152	radioligand-based	abstract[147]|abstract[148]|abstract[152]	new[147]|new[148]|new[152]	_	_
24-28	3153-3159	enzyme	abstract[147]|abstract[148]|substance|abstract[151]|abstract[152]	new[147]|new[148]|giv|new[151]|new[152]	_	_
24-29	3160-3168	kinetics	abstract[147]|abstract[148]|abstract[151]|abstract[152]	new[147]|new[148]|new[151]|new[152]	_	_
24-30	3169-3174	assay	abstract[147]|abstract[148]|abstract[152]	new[147]|new[148]|new[152]	_	_
24-31	3175-3176	,	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-32	3177-3191	size-exclusion	abstract[147]|abstract[148]|abstract|object[154]|abstract[156]	new[147]|new[148]|new|new[154]|new[156]	appos	24-38[0_156]
24-33	3192-3206	chromatography	abstract[147]|abstract[148]|object[154]|abstract[156]	new[147]|new[148]|new[154]|new[156]	_	_
24-34	3207-3218	multi-angle	abstract[147]|abstract[148]|abstract[156]	new[147]|new[148]|new[156]	_	_
24-35	3219-3224	light	abstract[147]|abstract[148]|object|abstract[156]	new[147]|new[148]|new|new[156]	_	_
24-36	3225-3235	scattering	abstract[147]|abstract[148]|abstract[156]	new[147]|new[148]|new[156]	_	_
24-37	3236-3237	(	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-38	3238-3246	SEC-MALS	abstract[147]|abstract[148]|abstract	new[147]|new[148]|giv	_	_
24-39	3247-3248	)	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-40	3249-3250	,	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-41	3251-3262	small-angle	abstract[147]|abstract[148]|abstract[159]	new[147]|new[148]|new[159]	appos	24-45[0_159]
24-42	3263-3268	X-ray	abstract[147]|abstract[148]|object|abstract[159]	new[147]|new[148]|new|new[159]	_	_
24-43	3269-3279	scattering	abstract[147]|abstract[148]|abstract[159]	new[147]|new[148]|new[159]	_	_
24-44	3280-3281	(	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-45	3282-3286	SAXS	abstract[147]|abstract[148]|abstract	new[147]|new[148]|giv	_	_
24-46	3287-3288	)	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-47	3289-3290	,	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-48	3291-3294	and	abstract[147]|abstract[148]	new[147]|new[148]	_	_
24-49	3295-3303	hydrogen	abstract[147]|abstract[148]|substance|abstract[164]	new[147]|new[148]|new|new[164]	appos	24-55[0_164]
24-50	3304-3305	–	abstract[147]|abstract[148]|abstract[164]	new[147]|new[148]|new[164]	_	_
24-51	3306-3315	deuterium	abstract[147]|abstract[148]|substance|abstract[164]	new[147]|new[148]|new|new[164]	_	_
24-52	3316-3324	exchange	abstract[147]|abstract[148]|event|abstract[164]	new[147]|new[148]|new|new[164]	_	_
24-53	3325-3342	mass-spectrometry	abstract[147]|abstract[148]|abstract[164]	new[147]|new[148]|new[164]	_	_
24-54	3343-3344	(	_	_	_	_
24-55	3345-3351	HDX-MS	abstract	giv	_	_
24-56	3352-3353	)	_	_	_	_
24-57	3354-3355	.	_	_	_	_
